New hope for Hard-to-Treat cancers? utidelone trial underway
NCT ID NCT04911907
First seen Apr 15, 2026 · Last updated Jun 19, 2026 · Updated 12 times
Summary
This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utidelone infusions for 5 days every 3 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Luhe Hospital, Capital Medical University
Beijing, China
-
Obstetrics and Gynecology Hospital, Capital Medical University
Beijing, China
-
Shanghai East Hospital of Tongji University
Shanghai, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
utidelone injection
What this could lead to
If successful, this could provide a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to all patients. The drug may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.